Resound Vivia 9 60S microRIE vs Yeasound RIC800

The Resound Vivia 9 60S microRIE is a premium prescription behind-the-ear hearing aid released in 2025, currently available at $3,798. In HearAdvisor's lab testing, it earned a B grade with a SoundScore of 3.9/5, ranking #27 of 36 prescription hearing aids tested. This device demonstrates a mixed performance profile in our testing. Own-voice comfort is a notable strength, scoring 3.4/5—a solid result that sits 0.65 points above the category average, which may appeal to users sensitive to the hollow or boomy sound of their own speech. Speech clarity in quiet environments also performs well at 3.4/5, slightly above the category average. However, the Vivia 9 shows significant limitations in challenging listening situations. Speech in noise scored just 1.1/5, falling 0.81 points below the prescription hearing aid average—a substantial gap that suggests difficulty in restaurants, group conversations, or other noisy environments. Feedback handling, while strong in absolute terms at 4.2/5, still lands 0.51 points below what we typically see from prescription devices. Music streaming quality is mixed at 2.6/5, essentially matching the category average. At this premium price point, the Vivia 9 faces stiff competition. Several same-priced alternatives, including the Phonak Sphere Infinio and Oticon Intent, achieved notably higher overall scores in our testing. Consumers prioritizing noise performance may want to explore these options or consider lower-priced alternatives like the Sennheiser All Day Clear that delivered stronger overall results in our lab.

The Yeasound RIC800 is a mid-priced OTC hearing aid that earned an A grade with a SoundScore of 4.8/5 in our lab testing, placing it #2 among 65 OTC devices tested. At $659, this behind-the-ear rechargeable device delivers performance that significantly outpaces the category average of 3.71/5. Speech clarity is a standout strength. The RIC800 scores 4.4/5 for speech in quiet—a strong result that sits 1.63 points above the OTC category average. Speech in noise performance is more mixed at 2.4/5, though this still lands 0.93 points above the typical OTC device. Music streaming is where this device truly excels, scoring 4.3/5 and outperforming the category average by a substantial 2.38 points—making it one of the better choices for consumers who frequently stream audio from their phone. Feedback handling is excellent at 5.0/5, meaning users shouldn't encounter whistling issues during normal wear. The tradeoff comes with own-voice comfort, which scores 2.1/5—a mixed result that falls 0.41 points below the category average. Some users may notice their own voice sounds more hollow or boomy than expected. The RIC800 earned a 2025 Expert's Choice Award and supports both iPhone and Android streaming. For consumers seeking strong speech performance and exceptional streaming quality in the OTC space, this device represents a compelling option. Those particularly sensitive to own-voice quality may want to compare alternatives, but overall performance places the RIC800 among the top tier of OTC hearing aids we've tested.